beta
Trial Radar AI
Clinical Trial NCT07255898 for Multiple Myeloma, Hematologic Malignancies is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies Phase 1 33 Randomized

Not yet recruiting
Clinical Trial NCT07255898 is designed to study Treatment for Multiple Myeloma, Hematologic Malignancies. This Phase 1 interventional study is not yet recruiting. Enrollment is planned to begin on December 1, 2025 until the study accrues 33 participants. Led by Sichuan Baili Pharmaceutical Co., Ltd., this study is expected to complete by December 1, 2027. The latest data from ClinicalTrials.gov was last updated on December 1, 2025.
Brief Summary
This study is an open, multicenter, non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics characteristics and preliminary efficacy of BL-M24D1 in patients with relapsed or refractory multiple myeloma and other hematologic malignancies.
Detailed Description
The study is divided into two phases: a dose escalation phase (Phase Ia) and an expansion cohort phase (Phase Ib).
Official Title

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics and Preliminary Efficacy of BL-M24D1 for Injection in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

Conditions
Multiple MyelomaHematologic Malignancies
Other Study IDs
  • BL-M24D1-103
NCT ID Number
NCT07255898
Start Date (Actual)
2025-12
Last Update Posted
2025-12-01
Completion Date (Estimated)
2027-12
Enrollment (Estimated)
33
Study Type
Interventional
PHASE
Phase 1
Status
Not yet recruiting
Primary Purpose
Treatment
Design Allocation
N/A
Interventional Model
Single Group
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalBL-M24D1
Participants receive BL-M24D1 as intravenous infusion for the first cycle (2 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
BL-M24D1
Administration by intravenous infusion for a cycle of 2 weeks.
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Phase Ia: Dose limiting toxicity (DLT)
DLTs are assessed according to NCI-CTCAE v5.0 during the first cycle and defined as occurrence of any of the toxicities in DLT definition if judged by the investigator to be possibly, probably or definitely related to study drug administration.
Up to 28 days after the first dose
Phase Ia: Maximum tolerated dose (MTD)
MTD is defined as the highest dose level at which no more than 1 in 6 participants experienced a DLT during the first cycle.
Up to 28 days after the first dose
Phase Ib: Recommended Phase II Dose (RP2D)
The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-M24D1.
Up to approximately 24 months
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Treatment-Emergent Adverse Event (TEAE)
TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-M24D1. The type, frequency and severity of TEAE will be evaluated during the treatment of BL-M24D1.
Up to approximately 24 months
Cmax
Maximum serum concentration (Cmax) of BL-M24D1 will be investigated.
Up to approximately 24 months
Tmax
Time to maximum serum concentration (Tmax) of BL-M24D1 will be investigated.
Up to approximately 24 months
T1/2
Half-life (T1/2) of BL-M24D1 will be investigated.
Up to approximately 24 months
AUC0-t
AUC0-t is defined as area under the serum concentration-time curve from time 0 to the time of the last measurable concentration.
Up to approximately 24 months
CL (Clearance)
CL in the serum of BL-M24D1 per unit of time will be investigated.
Up to approximately 24 months
Ctrough
Ctrough is defined as the lowest serum concentration of BL-M24D1 prior to the next dose will be administered.
Up to approximately 24 months
ADA (anti-drug antibody)
Frequency of anti-BL-M24D1 antibody (ADA) will be investigated.
Up to approximately 24 months
Phase Ib: Objective Response Rate (ORR)
ORR is defined as the percentage of participants, who has a CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1.
Up to approximately 24 months
Phase Ib: Duration of Response (DOR)
The DOR for a responder is defined as the time from the participant's initial objective response to the first date of either disease progression or death, whichever occurs first.
Up to approximately 24 months
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  1. Voluntarily sign the informed consent form and comply with the protocol requirements;
  2. Gender is not restricted;
  3. Age: ≥18 years and ≤75 years (Phase Ia); ≥18 years (Phase Ib);
  4. Expected survival time ≥3 months;
  5. Histologically and/or cytologically confirmed multiple myeloma or other hematologic malignancies that have failed standard treatment or for which no standard treatment currently exists;
  6. Must have measurable indicators as defined by the protocol;
  7. Physical condition score ECOG 0 or 1;
  8. Toxicity from previous antitumor treatments has recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;
  9. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
  10. Organ function levels must meet the requirements;
  11. Coagulation function: International Normalized Ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5 × ULN;
  12. For premenopausal women with childbearing potential, a pregnancy test must be conducted within 7 days before starting treatment, the serum pregnancy test must be negative, and they must not be breastfeeding; all enrolled patients (regardless of gender) should adopt adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.

  1. Subjects with central nervous system involvement, etc.;
  2. Use of chemotherapy, biologics, immunotherapy, etc., within 4 weeks prior to the first dose or within 5 half-lives;
  3. History of severe heart disease;
  4. QT interval prolongation, complete left bundle branch block, third-degree atrioventricular block;
  5. Active autoimmune diseases and inflammatory diseases;
  6. Diagnosis of other malignancies within 5 years prior to the first dose;
  7. Hypertension poorly controlled by two antihypertensive medications;
  8. Patients with poorly controlled blood glucose;
  9. Unstable thrombotic events requiring therapeutic intervention within 6 months prior to the first dose;
  10. Lung diseases defined as ≥ Grade 3 according to CTCAE v5.0; history of interstitial lung disease requiring hormone treatment, etc.;
  11. Patients with peripheral neuropathy ≥ Grade 3 or persistent ≥ Grade 2 peripheral neuropathy with pain;
  12. Patients with a history of allergy to recombinant humanized antibodies or human-mouse chimeric antibodies, or allergy to any excipient component of BL-M24D1;
  13. Previous organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT);
  14. Human immunodeficiency virus antibody positivity, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
  15. Active infection requiring systemic treatment within 4 weeks prior to the first study drug administration, etc.;
  16. Pleural, abdominal, pelvic, or pericardial effusion requiring drainage and/or accompanied by symptoms within 4 weeks prior to the first study drug administration;
  17. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks prior to the first study drug administration;
  18. Participation in another clinical trial within 4 weeks prior to the first dose;
  19. Pregnant or breastfeeding women;
  20. Patients who received live vaccines within 30 days prior to the first dose;
  21. Other conditions deemed by the investigator as unsuitable for participation in this clinical trial.
Sichuan Baili Pharmaceutical Co., Ltd. logoSichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. logoBaili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Study Central Contact
Contact: Sa Xiao, PHD, 15013238943, [email protected]
1 Study Locations in 1 Countries

Sichuan

West China Hospital of Sichuan University, Chengdu, Sichuan, China
Ting Niu, Contact